Background: Catch up growth is associated with glucose and lipid metabolism disorders, that can lead to osteoporosis and related fractures. Glucagon-like peptide-1 receptor agonists, such as liraglutide, exert an anabolic effect on bone in insulin resistant mice, but the mechanism for the action remains unclear. We established an animal model of catch-up growth to explore the actions of GLP-1 on bone mass and structure.

Methods: 30 male C57BL/6 mice were randomly divided into the normal diet (ND, n=10), the catch-up growth model (RH, n=10) and the catch-up growth model +GLP-1 (RH+GLP-1, n=10) groups. Liraglutide was subcutaneously administered (200ug/kg, twice a day, for four weeks). After killing, tibia and fibula were removed for bone histomorphometry, bilateral femoral bone marrow mesenchymal stem cells were collected to evaluate their differentiation ability.

Results: GLP-1 administration decreased weight of visceral fat tissue, body weight, ratio between them, and blood lipids of the RH group. GLP-1 decreased triglyceride levels, and fatty acids in the liver, visceral fat tissue, subcutaneous fat tissue and skeletal muscle tissue. Compared to the ND group, GLP-1 secretion decreased in the RH group, but noticeably increased after GLP-1 administration. The areas under curves of intraperitoneal glucose tolerance test and insulin tolerance test and HOMA-IR in RH+GLP-1 group significantly declined. GLP-1 reversed deteriorated tibial and fibular bone structure in RH mice and induced osteoblastic differentiation.

Conclusion: Decreased ability of osteoblastic/osteogenesis differentiation of MSCs in RH mice led to impaired bone formation and GLP-1 intervention reversed the damage and enhanced insulin sensitivity.


W. Xia: None. L. Chen: None. Q. Zhang: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at